MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Eric Risser

CEOEric Risser

Employees

341

Employees341

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

341

Employees341

MGNX Key Statistics

Market cap

125.88M

Market cap125.88M

Price-Earnings ratio

-1.64

Price-Earnings ratio-1.64

Dividend yield

—

Dividend yield—

Average volume

596.04K

Average volume596.04K

High today

$2.01

High today$2.01

Low today

$1.89

Low today$1.89

Open price

$1.92

Open price$1.92

Volume

605.90K

Volume605.90K

52 Week high

$2.63

52 Week high$2.63

52 Week low

$0.9897

52 Week low$0.9897

Stock Snapshot

MacroGenics(MGNX) stock is priced at $2.00, giving the company a market capitalization of 125.88M. It carries a P/E multiple of -1.64.

On 2026-02-27, MacroGenics(MGNX) stock moved within a range of $1.89 to $2.01. With shares now at $2.00, the stock is trading +5.7% above its intraday low and -0.3% below the session's peak.

Trading volume for MacroGenics(MGNX) stock has reached 605.9K, versus its average volume of 596.04K.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $2.63 and a low of $0.99.

MGNX News

TipRanks 3d

FDA Places Partial Clinical Hold on MacroGenics Trial

An update from MacroGenics ( (MGNX) ) is now available. On February 23, 2026, MacroGenics announced that the U.S. Food and Drug Administration placed a partial...

Benzinga 3d

Why Is MacroGenics Stock Sinking Tuesday?

MacroGenics Inc. (NASDAQ:MGNX) shares are down during Tuesday’s premarket session following the announcement of a partial clinical hold on its Phase 2 LINNET st...

TipRanks 3d

MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study

MacroGenics (MGNX) announced that the U. S. FDA has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific D...

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.